DE69933877D1 - Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung - Google Patents

Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung

Info

Publication number
DE69933877D1
DE69933877D1 DE69933877T DE69933877T DE69933877D1 DE 69933877 D1 DE69933877 D1 DE 69933877D1 DE 69933877 T DE69933877 T DE 69933877T DE 69933877 T DE69933877 T DE 69933877T DE 69933877 D1 DE69933877 D1 DE 69933877D1
Authority
DE
Germany
Prior art keywords
alpha
inducible factor
hypoxia
mutein
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933877T
Other languages
English (en)
Other versions
DE69933877T2 (de
Inventor
L Semenza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE69933877D1 publication Critical patent/DE69933877D1/de
Application granted granted Critical
Publication of DE69933877T2 publication Critical patent/DE69933877T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69933877T 1998-08-25 1999-08-25 Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung Expired - Lifetime DE69933877T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/148,547 US6124131A (en) 1998-08-25 1998-08-25 Mutant hypoxia inducible factor-1 HIF-1
US148547 1998-08-25
PCT/US1999/019416 WO2000010578A1 (en) 1998-08-25 1999-08-25 STABLE HYPOXIA INDUCIBLE FACTOR-1 alpha AND METHOD OF USE

Publications (2)

Publication Number Publication Date
DE69933877D1 true DE69933877D1 (de) 2006-12-14
DE69933877T2 DE69933877T2 (de) 2007-06-21

Family

ID=22526230

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933877T Expired - Lifetime DE69933877T2 (de) 1998-08-25 1999-08-25 Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung

Country Status (11)

Country Link
US (3) US6124131A (de)
EP (1) EP1107768B1 (de)
JP (1) JP2002523028A (de)
AT (1) ATE344043T1 (de)
AU (1) AU758627B2 (de)
CA (1) CA2340328C (de)
DE (1) DE69933877T2 (de)
IL (2) IL141494A0 (de)
NO (1) NO20010920L (de)
NZ (1) NZ510002A (de)
WO (1) WO2000010578A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
EP1353946A2 (de) * 2000-08-07 2003-10-22 Angiogenetics Sweden AB Mechanismus der konditionalen regulation des hypoxie-induzierbaren faktor-1 durch das von hippel-lindau tumor suppressor protein.
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
CA2446946A1 (en) 2001-05-09 2002-11-14 Anges Mg, Inc. Gene transfer of angiogenic factor for skin disease
WO2002094862A2 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
US6838430B2 (en) * 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
CN102552261A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
CN101518535A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005037217A2 (en) * 2003-10-17 2005-04-28 Actis Biologics, Inc. Lentiviral vector delivery of msp36 for treatment of cancer
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
EP1689436A1 (de) * 2003-11-26 2006-08-16 Entelos, Inc. BEHANDLUNG VON RHEUMATOIDER ARTHRITIS MIT HYPOXIE-INDUZIERBAREN FAKTOR a ANTAGONISTEN
US20050137568A1 (en) * 2003-12-17 2005-06-23 Jones Donald K. Activatable bioactive implantable medical device and method of use
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
JP2007516727A (ja) * 2003-12-31 2007-06-28 アクティス バイオロジクス， インコーポレイテッド 癌を処置するためのネイティブｉｇｆｂｐ−３および変異型ｉｇｆｂｐ−３のレンチウイルスベクター送達
US7247159B2 (en) * 2004-04-08 2007-07-24 Cordis Neurovascular, Inc. Activatable bioactive vascular occlusive device
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
WO2006130320A2 (en) * 2005-05-11 2006-12-07 University Of Florida Research Foundation, Inc. Repair of the bone marrow vasculature
ATE470439T1 (de) * 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
US20090215687A1 (en) * 2005-10-21 2009-08-27 Cornell Research Foundation, Inc. Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
JP5054092B2 (ja) * 2006-03-30 2012-10-24 エルジー エレクトロニクス インコーポレイティド ビデオ信号のデコーディング／エンコーディング方法及び装置
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
CN101516902B (zh) 2006-07-31 2012-08-08 脉管生物生长有限公司 多肽和其编码多聚核苷酸及它们在治疗缺血相关医学病症中的应用
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
SI2066791T1 (sl) 2006-10-03 2013-01-31 Genzyme Corporation Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
EP3334484A4 (de) 2015-08-12 2019-09-25 The General Hospital Corporation Zusammensetzungen und verfahren zur förderung der hypoxie oder der hypoxieantwort zur behandlung und vorbeugung von mitochondrialer dysfunktion und oxidativen stresserkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
NZ504847A (en) 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1

Also Published As

Publication number Publication date
CA2340328C (en) 2011-06-21
IL141494A (en) 2009-05-04
EP1107768A1 (de) 2001-06-20
AU758627B2 (en) 2003-03-27
NZ510002A (en) 2003-11-28
JP2002523028A (ja) 2002-07-30
US6124131A (en) 2000-09-26
IL141494A0 (en) 2002-03-10
WO2000010578A1 (en) 2000-03-02
AU5691499A (en) 2000-03-14
NO20010920L (no) 2001-04-23
NO20010920D0 (no) 2001-02-23
EP1107768A4 (de) 2004-12-29
DE69933877T2 (de) 2007-06-21
ATE344043T1 (de) 2006-11-15
US6562799B1 (en) 2003-05-13
US20030176349A1 (en) 2003-09-18
CA2340328A1 (en) 2000-03-02
EP1107768B1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE344043T1 (de) Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
LV10180A (lv) Farmaceitiska kompozicija
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
FI963871A (fi) Farmaseuttinen formulointi tekijän VIII tai tekijän IX antamiseksi ihonalaisesti, lihaksensisäisesti tai ihonsisäisesti
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
KR950701226A (ko) C-키트 수용체의 리간드 및 그의 사용방법
DE68926679T2 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
EE9900428A (et) Köhavastased ravimkoostised
DE69030387D1 (de) Chinoloncarbonsäure-metallionsäurekomplexe
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE94763T1 (de) Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69330809T2 (de) Therapeutisches Agens für Neutropenie
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition